Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Equity / Series A Common Stock, $0.0001 par value per share
Symbol
SGMT on Nasdaq
Shares outstanding
31,278,271
Price per share
$5.92
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
12,635,689
Total reported value
$86,680,189
% of total 13F portfolios
0%
Share change
+1,060,850
Value change
+$6,909,221
Number of holders
72
Price from insider filings
$5.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
AP11 Ltd 4.9% -10% $4,784,762 -$477,188 1,504,642 -9.1% AP11 Limited 24 Jun 2025
Woodline Partners LP 4.8% -44% $10,299,309 -$7,211,088 1,501,357 -41% Woodline Partners LP 30 Sep 2025
Blue Owl Capital Holdings LP 4.3% $3,058,156 1,323,877 Blue Owl Capital Holdings LP 31 Dec 2024

As of 30 Sep 2025, 72 institutional investors reported holding 12,635,689 shares of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT). This represents 40% of the company’s total 31,278,271 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Woodline Partners LP 4.8% 1,501,357 -41% 0.05% $10,299,309
Blue Owl Capital Holdings LP 4.2% 1,328,351 0% 2.8% $9,112,488
VANGUARD GROUP INC 3.8% 1,203,231 +4.3% 0% $8,254,165
BAKER BROS. ADVISORS LP 3% 952,996 0% 0.05% $6,537,553
MILLENNIUM MANAGEMENT LLC 2.5% 776,377 +926% 0% $5,325,946
HHLR ADVISORS, LTD. 2.3% 724,800 0% 0.12% $4,972,128
Siren, L.L.C. 2.3% 724,771 0% 0.19% $4,971,929
D. E. Shaw & Co., Inc. 2.2% 701,241 +387% 0% $4,810,513
BlackRock, Inc. 2% 612,717 +27% 0% $4,203,239
Schonfeld Strategic Advisors LLC 1.7% 523,774 +462% 0.03% $3,593,085
Affinity Asset Advisors, LLC 1.1% 350,000 0.22% $2,401,000
READYSTATE ASSET MANAGEMENT LP 1% 325,359 +21% 0.11% $2,231,963
UBS Group AG 0.98% 306,766 -46% 0% $2,104,415
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.96% 299,641 -27% 0.04% $2,055,537
GEODE CAPITAL MANAGEMENT, LLC 0.91% 283,213 +6.7% 0% $1,943,670
RAYMOND JAMES FINANCIAL INC 0.89% 278,246 +5.1% 0% $1,908,768
MORGAN STANLEY 0.79% 246,077 +26% 0% $1,688,089
RENAISSANCE TECHNOLOGIES LLC 0.52% 161,400 +422% 0% $1,107,204
AlphaQuest LLC 0.37% 117,259 0.05% $804,397
FNY Investment Advisers, LLC 0.35% 110,650 +28% 0.25% $759,000
STATE STREET CORP 0.35% 110,488 +11% 0% $757,948
Qube Research & Technologies Ltd 0.34% 106,846 0% $732,964
GSA CAPITAL PARTNERS LLP 0.27% 85,248 0.05% $585,000
XTX Topco Ltd 0.19% 59,734 +133% 0.02% $409,775
AMERICAN CENTURY COMPANIES INC 0.19% 58,459 +38% 0% $401,029

Institutional Holders of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 197,247 $1,162,530 +$193,833 $5.92 7
2025 Q3 12,635,689 $86,680,189 +$6,909,221 $6.86 72
2025 Q2 11,676,267 $88,988,335 +$3,493,944 $7.62 67
2025 Q1 13,776,513 $44,920,783 -$15,209,264 $3.26 69
2024 Q4 17,500,774 $78,763,978 -$8,862,759 $4.50 66
2024 Q3 19,656,790 $54,446,688 -$7,223,512 $2.77 63
2024 Q2 20,925,005 $71,568,169 -$7,440,674 $3.42 80
2024 Q1 22,609,183 $122,544,534 +$43,963,572 $5.42 81
2023 Q4 14,445,035 $76,117,702 -$8,913,863 $5.42 51
2023 Q3 15,566,944 $130,212,013 +$129,708,727 $8.80 47